首页 > 最新文献

Journal of Digestive Diseases最新文献

英文 中文
Ethnic Minority Disparities in the Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Representative Area of China.
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-16 DOI: 10.1111/1751-2980.13331
Jun Zhao Ye, Li Min Lin, Cong Xiang Shao, Sui Lin Mo, Miao Sheng Ye, Xiao Yi Li, Qing Li, Wen Geng Wang, Qiao Cong Zheng, Ke Luo, Yi Zhang, Shou Wei Tu, Dai Tuan Che, Ru Long Gong, Xing Chen, Rong Miu, Yan Hong Sun, Ting Feng Wu, Bi Hui Zhong

Objective: We aimed to evaluate the differences in clinical features and lifestyle between Han and ethnic minority populations in Guangdong Province, China and their impacts on the ever-growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD).

Methods: In this cross-sectional investigation in Guangdong Province, China, one of the most densely populated areas with imbalanced development, multistage stratified random sampling was used. Demographic, socioeconomic, and lifestyle data of participants were collected. Assessment of hepatic steatosis and liver stiffness measurement were performed.

Results: A total of 7287 individuals were recruited, including 7076 Han and 211 ethnic minority individuals, with similar MASLD prevalence between the two groups (35.8% vs 34.6%, p = 0.771). More ethnic minority individuals presented advanced fibrosis (≥ F3) overall and in subgroups of overweight/obesity, lean/normal weight, and males, but less advanced fibrosis in females and age of 30-34 years (all p < 0.05) than the Han Chinese. Proper physical activity was associated with a reduced risk of MASLD (Han: odds ratio [OR] 0.64, p = 0.021; ethnic minority: OR 0.06, p = 0.017). Sufficient sleep, drinking tea, and dietary fiber intake were protective factors for MASLD, while long sedentary duration, midnight snacks, dining out, and excessive intake of salt, red meat, and sugar were associated with a higher risk of MASLD in Han Chinese only.

Conclusions: There was a strikingly high burden of MASLD in the ethnic minority in Guangdong Province, China, and their lifestyle differences compared with Han Chinese may contribute to the epidemic surge of MASLD.

{"title":"Ethnic Minority Disparities in the Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Representative Area of China.","authors":"Jun Zhao Ye, Li Min Lin, Cong Xiang Shao, Sui Lin Mo, Miao Sheng Ye, Xiao Yi Li, Qing Li, Wen Geng Wang, Qiao Cong Zheng, Ke Luo, Yi Zhang, Shou Wei Tu, Dai Tuan Che, Ru Long Gong, Xing Chen, Rong Miu, Yan Hong Sun, Ting Feng Wu, Bi Hui Zhong","doi":"10.1111/1751-2980.13331","DOIUrl":"https://doi.org/10.1111/1751-2980.13331","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the differences in clinical features and lifestyle between Han and ethnic minority populations in Guangdong Province, China and their impacts on the ever-growing burden of metabolic dysfunction-associated steatotic liver disease (MASLD).</p><p><strong>Methods: </strong>In this cross-sectional investigation in Guangdong Province, China, one of the most densely populated areas with imbalanced development, multistage stratified random sampling was used. Demographic, socioeconomic, and lifestyle data of participants were collected. Assessment of hepatic steatosis and liver stiffness measurement were performed.</p><p><strong>Results: </strong>A total of 7287 individuals were recruited, including 7076 Han and 211 ethnic minority individuals, with similar MASLD prevalence between the two groups (35.8% vs 34.6%, p = 0.771). More ethnic minority individuals presented advanced fibrosis (≥ F3) overall and in subgroups of overweight/obesity, lean/normal weight, and males, but less advanced fibrosis in females and age of 30-34 years (all p < 0.05) than the Han Chinese. Proper physical activity was associated with a reduced risk of MASLD (Han: odds ratio [OR] 0.64, p = 0.021; ethnic minority: OR 0.06, p = 0.017). Sufficient sleep, drinking tea, and dietary fiber intake were protective factors for MASLD, while long sedentary duration, midnight snacks, dining out, and excessive intake of salt, red meat, and sugar were associated with a higher risk of MASLD in Han Chinese only.</p><p><strong>Conclusions: </strong>There was a strikingly high burden of MASLD in the ethnic minority in Guangdong Province, China, and their lifestyle differences compared with Han Chinese may contribute to the epidemic surge of MASLD.</p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Climate Sustainability as a Catalyst for Quality and Excellence in Gastrointestinal Endoscopy: A Narrative Review.
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-05 DOI: 10.1111/1751-2980.13330
Tiing Leong Ang

The significant contribution of greenhouse gas (GHG) emissions to global warming and the resultant negative impact on health is well established. Within the hospital setting, the endoscopy center has been ranked third-after the operating theater complex and intensive care unit-in terms of the volume of hazardous medical waste generated. Such regulated medical waste cannot be recycled, and the disposal process results in higher costs and a larger carbon footprint. There have been clarion calls to reduce the number of endoscopic procedures as a means of reducing GHG emissions. Previous studies have demonstrated the carbon footprint of inappropriate endoscopic procedures. However, endoscopy is an important diagnostic and therapeutic tool that has been shown to be cost-effective. A focus simply on reduction in procedural case volume alone raises the unintended consequences of inequitable access to endoscopy for those in need. A more nuanced approach that is aligned with the innate sense of healthcare professional aspirations and pride, in terms of seeking quality and clinical excellence, should be considered. An evidence-based approach, with a focus on quality and efficiency, as well as appropriate and timely use of new technology, will serve as a catalyst for positive behavioral change toward quality procedures and excellence. This will improve patient satisfaction, increase professional expertise and pride, and reduce carbon footprint through minimization of inappropriate and avoidable repeat procedures.

{"title":"Climate Sustainability as a Catalyst for Quality and Excellence in Gastrointestinal Endoscopy: A Narrative Review.","authors":"Tiing Leong Ang","doi":"10.1111/1751-2980.13330","DOIUrl":"https://doi.org/10.1111/1751-2980.13330","url":null,"abstract":"<p><p>The significant contribution of greenhouse gas (GHG) emissions to global warming and the resultant negative impact on health is well established. Within the hospital setting, the endoscopy center has been ranked third-after the operating theater complex and intensive care unit-in terms of the volume of hazardous medical waste generated. Such regulated medical waste cannot be recycled, and the disposal process results in higher costs and a larger carbon footprint. There have been clarion calls to reduce the number of endoscopic procedures as a means of reducing GHG emissions. Previous studies have demonstrated the carbon footprint of inappropriate endoscopic procedures. However, endoscopy is an important diagnostic and therapeutic tool that has been shown to be cost-effective. A focus simply on reduction in procedural case volume alone raises the unintended consequences of inequitable access to endoscopy for those in need. A more nuanced approach that is aligned with the innate sense of healthcare professional aspirations and pride, in terms of seeking quality and clinical excellence, should be considered. An evidence-based approach, with a focus on quality and efficiency, as well as appropriate and timely use of new technology, will serve as a catalyst for positive behavioral change toward quality procedures and excellence. This will improve patient satisfaction, increase professional expertise and pride, and reduce carbon footprint through minimization of inappropriate and avoidable repeat procedures.</p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-02 DOI: 10.1111/1751-2980.13329
Catherine Stankevicius, Rachel H Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S Day

Objectives: Sarcopenia increases the risk of nonalcoholic steatohepatitis (NASH) and cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD). Subsequently, poorly managed NAFLD can result in adverse health outcomes. Lifestyle interventions are effective for both NAFLD and sarcopenia; however, diagnosis of sarcopenia in this population is not well defined. This review aimed to examine current methods to diagnose sarcopenia in NAFLD patients.

Methods: MEDLINE, EMBASE, and CINAHL databases were searched for articles published until July 2023 using the terms "Non-alcoholic fatty liver disease," "NAFLD," "fatty liver," "sarcopenia," and "myoatrophy." Studies were excluded if they included pediatric populations, did not diagnose both sarcopenia and NAFLD, or included patients with alternate causes of liver disease.

Results: Twenty studies, predominantly from Asian countries (14 [70.0%]), involving 68 848 participants (45.5% females) were included. In 15 studies, most participants had a BMI > 25 kg/m2. Heterogeneity in the tools used to diagnose NAFLD was identified, with abdominal ultrasound being the most commonly used. European, Asian, and Australasian Sarcopenia Working Groups had differing diagnostic definitions of sarcopenia. Of the three potential diagnostic elements of sarcopenia (muscle mass, strength, function), all studies measured muscle mass, commonly through bioelectrical impedance analysis (12 [60.0%]). Seven studies (35.0%) measured muscle strength, with the majority (n = 6) utilizing hand grip strength. Four (20.0%) measured muscle function, through gait speed or a timed up-and-go test.

Conclusions: The lack of standardization in sarcopenia diagnosis for NAFLD patients is concerning. A consistent definition is necessary to prevent this comorbidity from being overlooked, improve care, and outcomes.

{"title":"Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?","authors":"Catherine Stankevicius, Rachel H Davis, Dep Huynh, Martine Hatzi, Stephanie Morgillo, Alice S Day","doi":"10.1111/1751-2980.13329","DOIUrl":"https://doi.org/10.1111/1751-2980.13329","url":null,"abstract":"<p><strong>Objectives: </strong>Sarcopenia increases the risk of nonalcoholic steatohepatitis (NASH) and cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD). Subsequently, poorly managed NAFLD can result in adverse health outcomes. Lifestyle interventions are effective for both NAFLD and sarcopenia; however, diagnosis of sarcopenia in this population is not well defined. This review aimed to examine current methods to diagnose sarcopenia in NAFLD patients.</p><p><strong>Methods: </strong>MEDLINE, EMBASE, and CINAHL databases were searched for articles published until July 2023 using the terms \"Non-alcoholic fatty liver disease,\" \"NAFLD,\" \"fatty liver,\" \"sarcopenia,\" and \"myoatrophy.\" Studies were excluded if they included pediatric populations, did not diagnose both sarcopenia and NAFLD, or included patients with alternate causes of liver disease.</p><p><strong>Results: </strong>Twenty studies, predominantly from Asian countries (14 [70.0%]), involving 68 848 participants (45.5% females) were included. In 15 studies, most participants had a BMI > 25 kg/m<sup>2</sup>. Heterogeneity in the tools used to diagnose NAFLD was identified, with abdominal ultrasound being the most commonly used. European, Asian, and Australasian Sarcopenia Working Groups had differing diagnostic definitions of sarcopenia. Of the three potential diagnostic elements of sarcopenia (muscle mass, strength, function), all studies measured muscle mass, commonly through bioelectrical impedance analysis (12 [60.0%]). Seven studies (35.0%) measured muscle strength, with the majority (n = 6) utilizing hand grip strength. Four (20.0%) measured muscle function, through gait speed or a timed up-and-go test.</p><p><strong>Conclusions: </strong>The lack of standardization in sarcopenia diagnosis for NAFLD patients is concerning. A consistent definition is necessary to prevent this comorbidity from being overlooked, improve care, and outcomes.</p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-26 DOI: 10.1111/1751-2980.13326
Meng Jie Gao, Song Bo Li, Xiao Jing Zhu, Li Feng Zhang, Min Chen, Yong Quan Shi

Objectives: To investigate the correlation between gastric xanthoma (GX) and precancerous lesions (PCL) and gastric cancer (GC), and to explore other potential risk factors for PCL and GC in northwest China.

Methods: A case-control study was conducted from September 2022 to September 2023 at Xijing Hospital, Air Force Medical University (Xi'an, Shaanxi Province, China). The patients who underwent gastroscopy were enrolled and divided into the chronic gastritis (CG) group (n = 423), PCL group (n = 422), and GC group (n = 415). The variables were selected through univariate analysis, including demographic information, dietary habits, lifestyle, gastroscopic findings, and Helicobacter pylori (H. pylori) infection. Multivariate logistic regression analysis was performed to analyze the factors associated with PCL and GC, and odds ratio (OR) and 95% confidence interval (CI) were calculated.

Results: GX was more prevalent in the PCL group (14.93%) and the GC group (19.76%) than in the CG group (6.15%). Multivariate analysis revealed that age ≥ 50 years, male gender, rural residence, H. pylori infection, family history of GC, GX, and hypertension were independent risk factors for GC and PCL. Furthermore, a diet high in salt and spice, coupled with daily intake of less than 100 g of fresh fruits, might be associated with the occurrence of GC.

Conclusion: Age ≥ 50 years, male gender, rural residence, family history of GC and H. pylori infection, presence of GX, and a history of hypertension may be risk factors for PCL and GC.

{"title":"Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.","authors":"Meng Jie Gao, Song Bo Li, Xiao Jing Zhu, Li Feng Zhang, Min Chen, Yong Quan Shi","doi":"10.1111/1751-2980.13326","DOIUrl":"https://doi.org/10.1111/1751-2980.13326","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the correlation between gastric xanthoma (GX) and precancerous lesions (PCL) and gastric cancer (GC), and to explore other potential risk factors for PCL and GC in northwest China.</p><p><strong>Methods: </strong>A case-control study was conducted from September 2022 to September 2023 at Xijing Hospital, Air Force Medical University (Xi'an, Shaanxi Province, China). The patients who underwent gastroscopy were enrolled and divided into the chronic gastritis (CG) group (n = 423), PCL group (n = 422), and GC group (n = 415). The variables were selected through univariate analysis, including demographic information, dietary habits, lifestyle, gastroscopic findings, and Helicobacter pylori (H. pylori) infection. Multivariate logistic regression analysis was performed to analyze the factors associated with PCL and GC, and odds ratio (OR) and 95% confidence interval (CI) were calculated.</p><p><strong>Results: </strong>GX was more prevalent in the PCL group (14.93%) and the GC group (19.76%) than in the CG group (6.15%). Multivariate analysis revealed that age ≥ 50 years, male gender, rural residence, H. pylori infection, family history of GC, GX, and hypertension were independent risk factors for GC and PCL. Furthermore, a diet high in salt and spice, coupled with daily intake of less than 100 g of fresh fruits, might be associated with the occurrence of GC.</p><p><strong>Conclusion: </strong>Age ≥ 50 years, male gender, rural residence, family history of GC and H. pylori infection, presence of GX, and a history of hypertension may be risk factors for PCL and GC.</p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease. 2型糖尿病和高血压是活检证实的代谢功能障碍相关脂肪变性肝病晚期纤维化的危险因素
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-13 DOI: 10.1111/1751-2980.13325
Yosuke Inukai, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Tatsuji Shimizu, Masashi Hattori, Tomoaki Takeyama, Yusuke Ando, Takahiro Nishikawa, Kiyoshi Morita, Hidenori Toyoda, Masatoshi Ishigami, Hiroki Kawashima

Objectives: To identify the diagnostic criteria for metabolic dysfunction-associated steatotic liver disease (MASLD) related to liver fibrosis and to characterize patients with cryptogenic steatotic liver disease (SLD) (non-MASLD) among those previously diagnosed with nonalcoholic fatty liver disease (NAFLD).

Methods: This multicenter retrospective study included 511 patients diagnosed with NAFLD via liver biopsy, and the prevalence of MASLD was assessed based on the diagnostic criteria. Patients were divided into those who met the MASLD criteria and those who did not, and the characteristics of advanced fibrosis and associated cardiometabolic factors were evaluated.

Results: Of the 475 patients with NAFLD, 458 (96.4%) met the criteria for MASLD, showing a high overlap between classical NAFLD and MASLD populations. Severe fibrosis was observed, regardless of the number of cardiometabolic factors. Hypertension and diabetes mellitus significantly contributed to advanced fibrosis (≥ F3), with odds ratio of 1.92 and 2.00 (95% confidence interval of 1.17-3.16 and 1.22-3.28, respectively; both p < 0.01) on multivariate analysis. The other seventeen (3.6%) patients did not meet the diagnostic criteria for MASLD. Among them, seven had significant fibrosis and a high fibrosis-4 index.

Conclusions: Diabetes mellitus and hypertension are key metabolic factors associated with advanced fibrosis. Some cases, classified as cryptogenic SLD, also exhibit significant fibrosis. Consequently, identifying high-risk patients, including those undergoing noninvasive tests for fibrosis, is crucial.

目的:确定与肝纤维化相关的代谢功能障碍相关脂肪变性肝病(MASLD)的诊断标准,并在先前诊断为非酒精性脂肪性肝病(NAFLD)的患者中确定隐源性脂肪变性肝病(SLD)(非MASLD)患者的特征。方法:本多中心回顾性研究纳入511例经肝活检诊断为NAFLD的患者,根据诊断标准评估MASLD的患病率。将患者分为符合MASLD标准的患者和不符合MASLD标准的患者,并评估晚期纤维化的特征和相关的心脏代谢因子。结果:475例NAFLD患者中,458例(96.4%)符合MASLD标准,典型NAFLD与MASLD人群有高度重叠。无论心脏代谢因子的数量如何,都观察到严重的纤维化。高血压和糖尿病显著促进晚期纤维化(≥F3),优势比分别为1.92和2.00(95%可信区间分别为1.17-3.16和1.22-3.28);结论:糖尿病和高血压是晚期纤维化的关键代谢因素。一些被归类为隐源性SLD的病例也表现出明显的纤维化。因此,识别高风险患者,包括那些接受无创纤维化检查的患者,至关重要。
{"title":"Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Yosuke Inukai, Takanori Ito, Shinya Yokoyama, Kenta Yamamoto, Norihiro Imai, Yoji Ishizu, Takashi Honda, Tatsuji Shimizu, Masashi Hattori, Tomoaki Takeyama, Yusuke Ando, Takahiro Nishikawa, Kiyoshi Morita, Hidenori Toyoda, Masatoshi Ishigami, Hiroki Kawashima","doi":"10.1111/1751-2980.13325","DOIUrl":"https://doi.org/10.1111/1751-2980.13325","url":null,"abstract":"<p><strong>Objectives: </strong>To identify the diagnostic criteria for metabolic dysfunction-associated steatotic liver disease (MASLD) related to liver fibrosis and to characterize patients with cryptogenic steatotic liver disease (SLD) (non-MASLD) among those previously diagnosed with nonalcoholic fatty liver disease (NAFLD).</p><p><strong>Methods: </strong>This multicenter retrospective study included 511 patients diagnosed with NAFLD via liver biopsy, and the prevalence of MASLD was assessed based on the diagnostic criteria. Patients were divided into those who met the MASLD criteria and those who did not, and the characteristics of advanced fibrosis and associated cardiometabolic factors were evaluated.</p><p><strong>Results: </strong>Of the 475 patients with NAFLD, 458 (96.4%) met the criteria for MASLD, showing a high overlap between classical NAFLD and MASLD populations. Severe fibrosis was observed, regardless of the number of cardiometabolic factors. Hypertension and diabetes mellitus significantly contributed to advanced fibrosis (≥ F3), with odds ratio of 1.92 and 2.00 (95% confidence interval of 1.17-3.16 and 1.22-3.28, respectively; both p < 0.01) on multivariate analysis. The other seventeen (3.6%) patients did not meet the diagnostic criteria for MASLD. Among them, seven had significant fibrosis and a high fibrosis-4 index.</p><p><strong>Conclusions: </strong>Diabetes mellitus and hypertension are key metabolic factors associated with advanced fibrosis. Some cases, classified as cryptogenic SLD, also exhibit significant fibrosis. Consequently, identifying high-risk patients, including those undergoing noninvasive tests for fibrosis, is crucial.</p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pancreatic panniculitis caused by pancreatic acinar cell carcinoma: A case report and literature review. 胰腺腺泡细胞癌致胰腺胰膜炎1例并文献复习。
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-01-02 DOI: 10.1111/1751-2980.13323
Bo Wen Tian, Si Zhe Li, Ge Chong Ruan, Tao Qu, Tao Wang, Yue Li
{"title":"Pancreatic panniculitis caused by pancreatic acinar cell carcinoma: A case report and literature review.","authors":"Bo Wen Tian, Si Zhe Li, Ge Chong Ruan, Tao Qu, Tao Wang, Yue Li","doi":"10.1111/1751-2980.13323","DOIUrl":"https://doi.org/10.1111/1751-2980.13323","url":null,"abstract":"","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case–control study in China 炎症性肠病患者自身免疫性肝病合并症的风险:中国一项单中心病例对照研究
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-28 DOI: 10.1111/1751-2980.13321
Meng Yuan Zhang, Tian Ming Xu, Ying Hao Sun, Xiao Tian Chu, Ge Chong Ruan, Xiao Yin Bai, Hong Lv, Hong Yang, Hui Jun Shu, Jia Ming Qian

Objective

To investigate the prevalence of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), and the impact of comorbidity of AIH, PBC, and PSC on hospitalization burden in patients with inflammatory bowel disease (IBD).

Methods

Inpatients admitted to Peking Union Medical College Hospital from January 1, 1998 to December 31, 2021 were included. Odds ratio (OR) and the corresponding 95% confidence interval (CI) were calculated to compare the risk of AIH, PBC, and PSC between IBD and non-IBD patients. Medical cost and length of hospitalization were compared between IBD patients with and without AIH, PBC, or PSC.

Results

Among the included 858 967 inpatients, there were 3059 patients with IBD. Additionally, there were 117 patients with AIH, 879 patients with PBC, and 35 patients with PSC, regardless of having IBD or not. Patients with IBD had a significantly higher risk of AIH (OR 4.87, 95% CI 1.20–19.71, p = 0.03) and PSC (OR 112.28, 95% CI 53.88–233.98, p < 0.01) than those without IBD. While there was no significant difference in the risk of PBC between patients with and without IBD (OR 1.60, 95% CI 0.67–3.86, p = 0.29). The medical cost of each hospitalization did not differ between IBD patients with and without AIH, PBC, or PSC.

Conclusions

IBD patients had a higher risk of AIH and PSC. Comorbidity of AIH, PBC, or PSC has no significant effect on the average cost of each hospitalization in IBD patients.

目的:探讨自身免疫性肝炎(AIH)、原发性胆管炎(PBC)和原发性硬化性胆管炎(PSC)的患病率,以及AIH、PBC和PSC合并症对炎症性肠病(IBD)患者住院负担的影响。方法:选取1998年1月1日至2021年12月31日北京协和医院住院患者。计算比值比(OR)和相应的95%置信区间(CI),比较IBD和非IBD患者之间AIH、PBC和PSC的风险。比较合并和不合并AIH、PBC或PSC的IBD患者的医疗费用和住院时间。结果:纳入的住院患者858967例中,IBD患者3059例。此外,有117例AIH患者,879例PBC患者和35例PSC患者,无论是否患有IBD。IBD患者发生AIH (OR 4.87, 95% CI 1.20 ~ 19.71, p = 0.03)和PSC (OR 112.28, 95% CI 53.88 ~ 233.98, p)的风险明显高于IBD患者。AIH、PBC或PSC的合并症对IBD患者每次住院的平均费用没有显著影响。
{"title":"Risk of comorbidity of autoimmune liver disease in patients with inflammatory bowel disease: A single-center case–control study in China","authors":"Meng Yuan Zhang,&nbsp;Tian Ming Xu,&nbsp;Ying Hao Sun,&nbsp;Xiao Tian Chu,&nbsp;Ge Chong Ruan,&nbsp;Xiao Yin Bai,&nbsp;Hong Lv,&nbsp;Hong Yang,&nbsp;Hui Jun Shu,&nbsp;Jia Ming Qian","doi":"10.1111/1751-2980.13321","DOIUrl":"10.1111/1751-2980.13321","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the prevalence of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), and the impact of comorbidity of AIH, PBC, and PSC on hospitalization burden in patients with inflammatory bowel disease (IBD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Inpatients admitted to Peking Union Medical College Hospital from January 1, 1998 to December 31, 2021 were included. Odds ratio (OR) and the corresponding 95% confidence interval (CI) were calculated to compare the risk of AIH, PBC, and PSC between IBD and non-IBD patients. Medical cost and length of hospitalization were compared between IBD patients with and without AIH, PBC, or PSC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the included 858 967 inpatients, there were 3059 patients with IBD. Additionally, there were 117 patients with AIH, 879 patients with PBC, and 35 patients with PSC, regardless of having IBD or not. Patients with IBD had a significantly higher risk of AIH (OR 4.87, 95% CI 1.20–19.71, <i>p</i> = 0.03) and PSC (OR 112.28, 95% CI 53.88–233.98, <i>p</i> &lt; 0.01) than those without IBD. While there was no significant difference in the risk of PBC between patients with and without IBD (OR 1.60, 95% CI 0.67–3.86, <i>p</i> = 0.29). The medical cost of each hospitalization did not differ between IBD patients with and without AIH, PBC, or PSC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>IBD patients had a higher risk of AIH and PSC. Comorbidity of AIH, PBC, or PSC has no significant effect on the average cost of each hospitalization in IBD patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":"25 9-10","pages":"587-593"},"PeriodicalIF":2.3,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the diagnostic efficacy between virtual portal pressure gradient and hepatic venous pressure gradient in patients with cirrhotic portal hypertension 虚门脉压梯度与肝静脉压梯度对肝硬化门脉高压诊断效果的比较。
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-26 DOI: 10.1111/1751-2980.13319
Wei Ping Song, Shuo Zhang, Jing Li, Yu Yang Shao, Ji Chong Xu, Chang Qing Yang

Objectives

This study aimed to evaluate the performance of virtual portal pressure gradient (vPPG) and its associated hemodynamic parameters of 3-dimensional (3D) model in patients with cirrhosis.

Methods

Seventy cirrhotic patients who underwent both hepatic venous pressure gradient (HVPG) measurement and vPPG calculation were prospectively collected. The ideal-state model (ISM; n = 44) was defined by sinusoidal PH without hepatic vein shunt or portal vein thrombosis, whereas those not conforming to the criteria were classified as non-ISM (n = 26). Correlation analyses were conducted to determine the relationship between vPPG or its associated 3D hemodynamic parameters and HVPG. The diagnostic and predictive performance of vPPG and HVPG for cirrhotic-related complications was evaluated using the receiver operating characteristic (ROC) curve and Kaplan–Meier analysis.

Results

In the ISM group, vPPG-associated hemodynamic parameters including total branch cross-sectional area (S2), average branch cross-sectional area (S), and average portal vein model length (h) were correlated with HVPG (r = 0.592, 0.536, −0.497; all p < 0.001), whereas vPPG was strongly correlated with HVPG (r = 0.832, p < 0.001). In the non-ISM group, vPPG, S2, S, and h were not related to HVPG (all p > 0.05). In the ISM group, both vPPG and HVPG showed significant diagnostic and predictive capabilities for cirrhosis-related complications. While in the non-ISM group, the diagnostic accuracy and predictive efficacy of vPPG surpassed those of HVPG.

Conclusion

HVPG exhibited superior diagnostic and predictive efficacy for cirrhotic PH in the ISM, whereas vPPG showed enhanced performance in non-ISM.

目的:本研究旨在评价三维(3D)模型虚拟门静脉压力梯度(vPPG)在肝硬化患者中的表现及其相关血流动力学参数。方法:前瞻性收集70例肝硬化患者进行肝静脉压梯度(HVPG)测量和vPPG计算。理想状态模型(ISM;n = 44)以PH值为正弦值,无肝静脉分流或门静脉血栓形成,不符合标准者为非ism (n = 26)。通过相关分析确定vPPG或其相关三维血流动力学参数与HVPG的关系。采用受试者工作特征(ROC)曲线和Kaplan-Meier分析评估vPPG和HVPG对肝硬化相关并发症的诊断和预测性能。结果:ISM组vppg相关血流动力学参数总分支横截面积(S2)、平均分支横截面积(S)、门静脉模型平均长度(h)与HVPG相关(r = 0.592, 0.536, -0.497;p < 0.05)。在ISM组中,vPPG和HVPG均显示出对肝硬化相关并发症的诊断和预测能力。而在非ism组,vPPG的诊断准确性和预测效果优于HVPG。结论:HVPG在ISM中对肝硬化PH具有优越的诊断和预测功效,而vPPG在非ISM中表现出更强的性能。
{"title":"Comparison of the diagnostic efficacy between virtual portal pressure gradient and hepatic venous pressure gradient in patients with cirrhotic portal hypertension","authors":"Wei Ping Song,&nbsp;Shuo Zhang,&nbsp;Jing Li,&nbsp;Yu Yang Shao,&nbsp;Ji Chong Xu,&nbsp;Chang Qing Yang","doi":"10.1111/1751-2980.13319","DOIUrl":"10.1111/1751-2980.13319","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to evaluate the performance of virtual portal pressure gradient (vPPG) and its associated hemodynamic parameters of 3-dimensional (3D) model in patients with cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Seventy cirrhotic patients who underwent both hepatic venous pressure gradient (HVPG) measurement and vPPG calculation were prospectively collected. The ideal-state model (ISM; n = 44) was defined by sinusoidal PH without hepatic vein shunt or portal vein thrombosis, whereas those not conforming to the criteria were classified as non-ISM (n = 26). Correlation analyses were conducted to determine the relationship between vPPG or its associated 3D hemodynamic parameters and HVPG. The diagnostic and predictive performance of vPPG and HVPG for cirrhotic-related complications was evaluated using the receiver operating characteristic (ROC) curve and Kaplan–Meier analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the ISM group, vPPG-associated hemodynamic parameters including total branch cross-sectional area (S2), average branch cross-sectional area (S), and average portal vein model length (h) were correlated with HVPG (<i>r</i> = 0.592, 0.536, −0.497; all <i>p</i> &lt; 0.001), whereas vPPG was strongly correlated with HVPG (<i>r</i> = 0.832, <i>p</i> &lt; 0.001). In the non-ISM group, vPPG, S2, S, and h were not related to HVPG (all <i>p</i> &gt; 0.05). In the ISM group, both vPPG and HVPG showed significant diagnostic and predictive capabilities for cirrhosis-related complications. While in the non-ISM group, the diagnostic accuracy and predictive efficacy of vPPG surpassed those of HVPG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>HVPG exhibited superior diagnostic and predictive efficacy for cirrhotic PH in the ISM, whereas vPPG showed enhanced performance in non-ISM.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":"25 9-10","pages":"603-614"},"PeriodicalIF":2.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical decision support tool-guided, selective intensive induction strategy of ustekinumab in patients with Crohn's disease: A multicenter cohort study 临床决策支持工具指导下,ustekinumab在克罗恩病患者中的选择性强化诱导策略:一项多中心队列研究
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-22 DOI: 10.1111/1751-2980.13318
Qing Li, Jian Tang, Zhao Peng Huang, Li Shuo Shi, Xiao Ping Lyu, Xue Min Chen, Wen Ke Chen, An Ying Xun, Qin Guo, Miao Li, Xiang Gao, Kang Chao

Objectives

We aimed to evaluate the effectiveness and safety of clinical decision support tool (CDST)-guided initial selective intensive induction therapy (IIT) for patients with Crohn's disease (CD) who were treated with ustekinumab (UST) and to identify those most likely to benefit from IIT.

Methods

Patients with active CD were included in this multicenter retrospective study and were categorized as low-, intermediate-, and high-probability responders according to the UST-CDST. IIT was defined as intensive induction by two or three initial doses of weight-based intravenous UST administration. Patients treated with standard therapy (ST) served as controls. The primary end-point was corticosteroid-free clinical remission (CFCR) at Week 24. Secondary end-points included clinical remission, clinical response, endoscopic remission, endoscopic response, and C-reactive protein (CRP) normalization at Week 24. Propensity score adjustments was conducted to ensure comparability.

Results

A total of 296 patients were included. At Week 24, IIT was associated with higher rates of CFCR (72.3% vs 43.0%, p < 0.001), clinical remission (77.3% vs 47.1%, p < 0.001), clinical response (78.1% vs 60.1%, p = 0.001), endoscopic remission (26.1% vs 9.9%, p = 0.024), and endoscopic response (58.6% vs 36.9%, p = 0.018) in low–intermediate-probability responders compared with ST. CRP normalization was comparable between groups. No significant differences were found in any end-points in high-probability responders. No serious adverse events were observed.

Conclusion

The efficacy of IIT was superior to that of ST in patients with predicted poor response to UST, which may be regarded as a novel strategy for stratifying patients at baseline.

目的:我们旨在评估临床决策支持工具(CDST)引导的初始选择性强化诱导治疗(IIT)对接受ustekinumab (UST)治疗的克罗恩病(CD)患者的有效性和安全性,并确定最有可能从IIT中获益的患者。方法:活动性CD患者被纳入这项多中心回顾性研究,并根据UST-CDST分为低、中、高概率应答者。IIT被定义为通过两到三次初始剂量的基于体重的静脉给药来强化诱导。采用标准治疗(ST)的患者作为对照组。主要终点是第24周无皮质类固醇临床缓解(CFCR)。次要终点包括临床缓解、临床反应、内窥镜缓解、内窥镜反应和第24周c反应蛋白(CRP)正常化。进行倾向得分调整以确保可比性。结果:共纳入296例患者。在第24周,IIT与较高的CFCR发生率相关(72.3% vs 43.0%), p结论:在预测对UST反应较差的患者中,IIT的疗效优于ST,这可能被视为基线患者分层的新策略。
{"title":"Clinical decision support tool-guided, selective intensive induction strategy of ustekinumab in patients with Crohn's disease: A multicenter cohort study","authors":"Qing Li,&nbsp;Jian Tang,&nbsp;Zhao Peng Huang,&nbsp;Li Shuo Shi,&nbsp;Xiao Ping Lyu,&nbsp;Xue Min Chen,&nbsp;Wen Ke Chen,&nbsp;An Ying Xun,&nbsp;Qin Guo,&nbsp;Miao Li,&nbsp;Xiang Gao,&nbsp;Kang Chao","doi":"10.1111/1751-2980.13318","DOIUrl":"10.1111/1751-2980.13318","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We aimed to evaluate the effectiveness and safety of clinical decision support tool (CDST)-guided initial selective intensive induction therapy (IIT) for patients with Crohn's disease (CD) who were treated with ustekinumab (UST) and to identify those most likely to benefit from IIT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with active CD were included in this multicenter retrospective study and were categorized as low-, intermediate-, and high-probability responders according to the UST-CDST. IIT was defined as intensive induction by two or three initial doses of weight-based intravenous UST administration. Patients treated with standard therapy (ST) served as controls. The primary end-point was corticosteroid-free clinical remission (CFCR) at Week 24. Secondary end-points included clinical remission, clinical response, endoscopic remission, endoscopic response, and C-reactive protein (CRP) normalization at Week 24. Propensity score adjustments was conducted to ensure comparability.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 296 patients were included. At Week 24, IIT was associated with higher rates of CFCR (72.3% vs 43.0%, <i>p</i> &lt; 0.001), clinical remission (77.3% vs 47.1%, <i>p</i> &lt; 0.001), clinical response (78.1% vs 60.1%, <i>p</i> = 0.001), endoscopic remission (26.1% vs 9.9%, <i>p</i> = 0.024), and endoscopic response (58.6% vs 36.9%, <i>p</i> = 0.018) in low–intermediate-probability responders compared with ST. CRP normalization was comparable between groups. No significant differences were found in any end-points in high-probability responders. No serious adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The efficacy of IIT was superior to that of ST in patients with predicted poor response to UST, which may be regarded as a novel strategy for stratifying patients at baseline.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":"25 9-10","pages":"594-602"},"PeriodicalIF":2.3,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare digestive disease: Mitochondrial neurogastrointestinal encephalomyopathy, review of the literature 罕见消化系统疾病:线粒体神经胃肠道脑肌病,文献综述。
IF 2.3 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-12-18 DOI: 10.1111/1751-2980.13317
Ying Hao Sun, Xiao Yin Bai, Tao Guo, Si Yuan Fan, Ge Chong Ruan, Wei Xun Zhou, Hong Yang

The median age of patients at diagnosis of mitochondrial neurogastrointestinal encephalomyopathy was 25 years. The most common neurological symptoms were leukoencephalopathy (83.1%), polyneuropathy (68.5%), and ptosis/ophthalmoparesis (61.8%). And the most common digestive symptoms were weight loss/cachexia (71.9%), abdominal pain (58.4%), diarrhea (57.3%), vomiting (53.9%), and constipation (13.5%).

诊断为线粒体神经胃肠道脑肌病的患者中位年龄为25岁。最常见的神经症状是白质脑病(83.1%)、多神经病变(68.5%)和上睑下垂/眼麻痹(61.8%)。最常见的消化系统症状为体重减轻/恶病质(71.9%)、腹痛(58.4%)、腹泻(57.3%)、呕吐(53.9%)和便秘(13.5%)。
{"title":"Rare digestive disease: Mitochondrial neurogastrointestinal encephalomyopathy, review of the literature","authors":"Ying Hao Sun,&nbsp;Xiao Yin Bai,&nbsp;Tao Guo,&nbsp;Si Yuan Fan,&nbsp;Ge Chong Ruan,&nbsp;Wei Xun Zhou,&nbsp;Hong Yang","doi":"10.1111/1751-2980.13317","DOIUrl":"10.1111/1751-2980.13317","url":null,"abstract":"<p>The median age of patients at diagnosis of mitochondrial neurogastrointestinal encephalomyopathy was 25 years. The most common neurological symptoms were leukoencephalopathy (83.1%), polyneuropathy (68.5%), and ptosis/ophthalmoparesis (61.8%). And the most common digestive symptoms were weight loss/cachexia (71.9%), abdominal pain (58.4%), diarrhea (57.3%), vomiting (53.9%), and constipation (13.5%).\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":15564,"journal":{"name":"Journal of Digestive Diseases","volume":"25 9-10","pages":"624-631"},"PeriodicalIF":2.3,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Digestive Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1